PharmaBoardroom

Kevin Rufang Huang is the president and founder of the Chinese Organization for Rare Disorders (CORD). A rare disease patient himself, he is…

Drug development in rare diseases is currently in a very exciting time. While much of the focus is on the scientific advances, access to rare…

What do executive recruitment firms look for when hiring country managers for multinational pharma companies in some of the world’s most challenging…

Silvia Casellas, CEO of Anagram, a Spanish CRO, discusses the challenges of the consolidation process the company has gone in recent years, the…

The Middle East and North Africa (MENA) region’s pharmaceutical market is projected to reach a value of around USD 60 billion by 2025 according to…

Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to…

Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India's ambitious healthcare insurance scheme,…

Teresa Chavarria Gimenez, director general of planning, research and training at the Ministry of Health of the Community of Madrid, highlights her…

Dr John Gong, CEO of 3D Medicines, shares the company’s ‘3D – diagnostics, data, and drug development’ approach to cancer precision medicine;…

LG Life Sciences is one the early pioneers of innovative drug development in Korea with a diversified portfolio of chemical drugs, vaccines,…

Rafael Mella, general manager of Nordic Pharma Spain & Portugal, highlights the steps he has taken to set-up the foundations for the company in…

As we move further into 2019, Emmanuel Fombu, MD, MBA: Author and Global Commercial Strategy and Digital Innovation Leader at Johnson and Johnson,…